Literature DB >> 33078375

Systemic Inflammatory Burden Correlates with Severity and Predicts Outcomes in Patients with Cardiogenic Shock Supported by a Percutaneous Mechanical Assist Device.

Nikolaos A Diakos1, Katherine Thayer1, Lija Swain1, Maithri Goud1, Pankaj Jain1, Navin K Kapur2,3.   

Abstract

In-hospital mortality associated with cardiogenic shock (CS) remains high despite introduction of mechanical circulatory support. In this study, we aimed to investigate whether systemic inflammation is associated with clinical outcomes in CS. We retrospectively analyzed systemic cytokine levels and the neutrophil-to-lymphocyte ratio (NLR), a marker of low-grade inflammation, among 134 patients with CS supported by VA-ECMO or Impella. Sixty-one percent of patients survived CS and either underwent device explantation or were bridged to LVAD or cardiac transplant. IL6 was the predominant circulating cytokine. IL6 levels were reduced after circulatory support in survivors. NLR pre-device implantation was significantly lower in patients with earlier stages of cardiogenic shock. Compared with non-survivors, survivors had a lower pre-device NLR and NLR was independently predictive of survival after adjusting for other covariates. In summary, NLR is a widely available marker of inflammation and correlates with in-hospital mortality among patients with cardiogenic shock requiring percutaneous mechanical circulatory support. Graphical Abstract Survivors present with lower NLR levels prior to percutaneous device implantation. Both survivors and non survivors present with elevated IL6 levels. IL6 levels decrease after percutaneous support (ECMO or Impella) only in survivors and continue to rise in non-survivors.

Entities:  

Keywords:  Cardiogenic shock; Heart failure; Inflammation; Mechanical circulatory support

Mesh:

Substances:

Year:  2020        PMID: 33078375     DOI: 10.1007/s12265-020-10078-5

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   3.216


  17 in total

Review 1.  Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm.

Authors:  Judith S Hochman
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

2.  SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.

Authors:  David A Baran; Cindy L Grines; Steven Bailey; Daniel Burkhoff; Shelley A Hall; Timothy D Henry; Steven M Hollenberg; Navin K Kapur; William O'Neill; Joseph P Ornato; Kelly Stelling; Holger Thiele; Sean van Diepen; Srihari S Naidu
Journal:  Catheter Cardiovasc Interv       Date:  2019-05-19       Impact factor: 2.692

3.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.

Authors:  Paul M Ridker; Brendan M Everett; Tom Thuren; Jean G MacFadyen; William H Chang; Christie Ballantyne; Francisco Fonseca; Jose Nicolau; Wolfgang Koenig; Stefan D Anker; John J P Kastelein; Jan H Cornel; Prem Pais; Daniel Pella; Jacques Genest; Renata Cifkova; Alberto Lorenzatti; Tamas Forster; Zhanna Kobalava; Luminita Vida-Simiti; Marcus Flather; Hiroaki Shimokawa; Hisao Ogawa; Mikael Dellborg; Paulo R F Rossi; Roland P T Troquay; Peter Libby; Robert J Glynn
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

Review 4.  Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association.

Authors:  Sean van Diepen; Jason N Katz; Nancy M Albert; Timothy D Henry; Alice K Jacobs; Navin K Kapur; Ahmet Kilic; Venu Menon; E Magnus Ohman; Nancy K Sweitzer; Holger Thiele; Jeffrey B Washam; Mauricio G Cohen
Journal:  Circulation       Date:  2017-09-18       Impact factor: 29.690

Review 5.  Role of innate and adaptive immune mechanisms in cardiac injury and repair.

Authors:  Slava Epelman; Peter P Liu; Douglas L Mann
Journal:  Nat Rev Immunol       Date:  2015-02       Impact factor: 53.106

6.  Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy.

Authors:  Marc S Sabatine; David A Morrow; Christopher P Cannon; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; Eugene Braunwald; C Michael Gibson
Journal:  J Am Coll Cardiol       Date:  2002-11-20       Impact factor: 24.094

7.  Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit.

Authors:  Cornelis P C de Jager; Paul T L van Wijk; Rejiv B Mathoera; Jacqueline de Jongh-Leuvenink; Tom van der Poll; Peter C Wever
Journal:  Crit Care       Date:  2010-10-29       Impact factor: 9.097

8.  Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study.

Authors:  Nicolas Moreau; Xavier Wittebole; Yvan Fleury; Patrice Forget; Pierre-François Laterre; Diego Castanares-Zapatero
Journal:  Shock       Date:  2018-04       Impact factor: 3.454

9.  The utility of neutrophil to lymphocyte ratio and fluid sequestration as an early predictor of severe acute pancreatitis.

Authors:  Chaoqun Han; Jun Zeng; Rong Lin; Jun Liu; Wei Qian; Zhen Ding; Xiaohua Hou
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

10.  Relationship between pre-implant interleukin-6 levels, inflammatory response, and early outcome in patients supported by left ventricular assist device: a prospective study.

Authors:  Raffaele Caruso; Luca Botta; Alessandro Verde; Filippo Milazzo; Irene Vecchi; Maria Giovanna Trivella; Luigi Martinelli; Roberto Paino; Maria Frigerio; Oberdan Parodi
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.